Overview
The objective of this study is to investigate the safety and effectiveness in routine clinical practice and actual clinical setting for all patients with rheumatoid arthritis (RA) treated with peficitinib.
Description
This is a mandatory Post-Marketing Surveillance (PMS) requested by Pharmaceuticals and Medical Devices Agency (PMDA) as a part of the Japan-Risk Management Plan (J-RMP).
Eligibility
Inclusion Criteria:
- All patients with rheumatoid arthritis (RA) treated with peficitinib for the first time.
Exclusion Criteria:
- Not applicable.